MaaT Pharma's Presentation of MaaT013 Outcomes
MaaT Pharma, a prominent clinical-stage biotechnology firm dedicated to advancing Microbiome Ecosystem Therapies, is gearing up to showcase significant findings from its Early Access Program involving the treatment MaaT013. With a focus on addressing the needs of patients suffering from gastrointestinal acute Graft-versus-Host Disease (GI-aGvHD), the results highlight a promising improvement in prolonged survival rates among those undergoing treatment.
Understanding Acute GvHD
Acute Graft-versus-Host Disease is a serious condition that can develop post-stem cell or bone marrow transplant. It emerges when the transplanted immune cells attack the recipient’s body, leading to severe inflammation, particularly in the skin, liver, and gastrointestinal tract. GI-aGvHD, a severe form of this condition, results in debilitating symptoms like high-volume diarrhea, posing a significant risk to affected individuals.
Insight into the Early Access Program
The results being shared from the Early Access Program involve data from 154 patients with steroid-refractory or dependent GI-aGvHD. This patient cohort had previously undergone a variety of treatment lines, often reaching severe stages of the disease—47% were diagnosed with grade III and 40% with grade IV aGvHD.
Impressive Survival Rates
The findings indicate that MaaT013 has strong potential as a transformative therapy. The gastrointestinal overall response rate (GI-ORR) reached 51%, with 30% of patients showing complete response (CR) after just 28 days of treatment. Moreover, overall survival (OS) percentages were encouraging, with notable rates of 53% at the six-month mark, 47% at 12 months, and 42% at 24 months.
Comparative Analysis of Treatment Responses
In analyzing subgroups, those receiving the second-line treatment known as ruxolitinib displayed even better responsiveness—59% GI-ORR on day 28. The numbers show that responders to MaaT013 exhibited significantly better survival outcomes (75% at 12 months) compared to non-responders.
A Positive Future for GvHD Treatment
Dr. Gianfranco Pittari, the Chief Medical Officer at MaaT Pharma, expressed optimism regarding the ongoing Phase 3 ARES trial. The positive results generated by MaaT013 not only highlight its potential effectiveness but also reaffirm the company’s commitment to pioneering microbiome-based therapies.
Upcoming Presentations and Conferences
MaaT Pharma has a number of conferences lined up where they will disseminate more information regarding their innovative approaches. In December, they will present at the 66th American Society of Hematology (ASH) Annual Meeting, where further detailed data about the Early Access Program will be uncovered.
About the Company
Founded in 2014 and based in Lyon, France, MaaT Pharma is dedicated to researching and developing advanced gut microbiome therapies aimed at improving cancer patient survival. Through their novel pooling and co-cultivation technologies, the company is at the forefront of integrating microbiome-driven techniques into oncology treatment protocols.
Frequently Asked Questions
What is MaaT013?
MaaT013 is a standardized, pooled-donor enema microbiome ecosystem therapy designed to help treat acute GvHD.
What were the results of the treatment?
The treatment showed an overall response rate of 51% and significant improvements in overall survival rates among treated patients.
What is the significance of GI-aGvHD?
GI-aGvHD is a severe complication following transplants leading to high morbidity and mortality due to its critical gastrointestinal effects.
Who presented the data on MaaT013?
The data will be presented by Professor Florent Malard at the upcoming ASH conference in December.
What is the future of MaaT Pharma?
MaaT Pharma aims to expand its research and enhance its microbiome therapy offerings, focusing on improving treatment outcomes for cancer patients.
